Amerise Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.10 Cr
- Paid Up Capital ₹ 4.87 Cr
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 211.68%
- Profit Growth 533.11%
- Ebitda 183.18%
- Net Worth 8373.29%
- Total Assets 75.18%
About Amerise Pharmaceuticals
Amerise Pharmaceuticals Private Limited (APPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 09 October 2018 (Six years and three months 28 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.10 Cr and a paid-up capital of Rs 4.87 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nirav Vyas and Jalpaben Vyas serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U36900GJ2018PTC104672
-
Company No.
104672
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Oct 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Amerise Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirav Vyas
|
Director | 04-Sep-2021 | Current |
|
Jalpaben Vyas
|
Director | 09-Oct-2018 | Current |
Financial Performance of Amerise Pharmaceuticals.
Amerise Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 211.68% increase. The company also saw a substantial improvement in profitability, with a 533.11% increase in profit. The company's net worth Soared by an impressive increase of 8373.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amerise Pharmaceuticals?
In 2021, Amerise Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Amuna Pharmaceuticals LlpNirav Vyas and Jalpaben Vyas are mutual person
-
Amerigen Life Sciences LlpNirav Vyas and Jalpaben Vyas are mutual person
-
Avimn Pharmaceuticals Llp
Nirav Vyas is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Amerise Pharmaceuticals?
Amerise Pharmaceuticals has a workforce of 3 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amerise Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amerise Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
